Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.
Key facts
- Registry number
- NCT06441331
- Stage of testing
- Phase 1
- Conditions studied
- Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Where it is running
This trial lists 6 sites.
-
California
- UCSF Benioff Children's Hospital (San Francisco)
-
France
- Gustave Roussy Cancer Campus (Villejuif)
-
Pennsylvania
- The Children's Hospital of Philadelphia (CHOP) (Philadelphia)
-
Spain
- Hospital Universitario Vall d'Hebron - Oncología Médica (Barcelona)
- Hospital General Universitario Gregorio Marañón (Madrid)
-
Texas
- University of Texas - MD Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.